Sanofi commits 100 million doses of hydroxychloroquine

Sanofi has committed to donate 100 million doses of hydroxychloroquine across 50 countries to support fight against Covid-19.

The company increased its production capacity by 50% and is making preparations to further boost production over the coming months.

If ongoing clinical trials demonstrate hydroxychloroquine’s safety and efficacy in Covid-19, Sanofi will continue to donate the drug to governments and hospitals.

Sanofi CEO Paul Hudson said: “It is critical that international authorities, local governments, manufacturers, and all the other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it.

Covid-19 Report — Updated twice a week Understanding the Covid-19 outbreak, the economic impact and implications for specific sectors

Get the free report

Our parent business intelligence company

“If the trials prove positive, we hope our donation will play a critical role for patients.”

Meanwhile, the US National Institutes of Health started the ORCHID Study of hydroxychloroquine to treat adults hospitalised with Covid-19.